News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Charity funding could help establish new clinical trials for deadliest of all childhood cancers
The Institute of Cancer Research, London has been awarded £2.5 million by the charity Brain Tumour Research to help find new treatments and pave the way towards a cure for the childhood cancer high grade glioma, a type of brain tumour.
Scientists discover a new way to help prevent breast cancer ‘time bomb’
Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep - forming incurable secondary tumours.
Algorithm offers new way to spot patients likely to respond to immunotherapy
Scientists have developed a new way of using cancers’ DNA to spot cancer patients who may benefit from immunotherapy.
Gene test could guide use of cancer chemotherapy
A gene test already used routinely in the NHS can guide use of chemotherapy in people with bowel cancer by predicting whether or not they will benefit.
New study unveils epigenetic ‘traffic lights’ controlling stop and go for gene activity
A major new study in the journal Nature reveals a ‘traffic light’ mechanism controlling genetic activity within cells – a system which could potentially be targeted by cancer drugs already in development.
Expectations for population-wide gene testing need to be realistic, say researchers
Testing a population for multiple genes at once will always be limited in its ability to accurately predict disease risk, experts are warning.
Scientists reveal how different cancer cells ‘team up’ to help incurable childhood brain tumour spread
Scientists have shed light on how different types of cancer cells in an aggressive childhood brain cancer interact and work together to spread.
‘Molecular glue degrader’ reaches cancer trial following ICR research programme
The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology.
Meet our scientists at upcoming industry collaboration events
Upcoming events will give industry experts the chance to hear from some of our leading researchers about opportunities to work with them.
Urinary and sexual side effects less likely after advanced radiotherapy than surgery for advanced prostate cancer patients
Men with prostate cancer are less likely to experience urinary and sexual side effects two years after treatment with an advanced type of radiotherapy than surgery, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
Mobile health checks could speed up diagnosis of prostate cancer
Data from a pilot study suggestthe ‘Man Van’, an innovative targeted outreach programme, could improve healthcare access for men and potentially speed up the detection of prostate cancer.
Strong family history of prostate cancer linked to better survival
Being aware of a strong family history of prostate cancer is linked to an increased chance of surviving the disease, new research suggests.
